Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E PIK3CA N1044S |
| Therapy | GSK2334470 + Trametinib |
| Indication/Tumor Type | anaplastic thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E PIK3CA N1044S | anaplastic thyroid carcinoma | sensitive | GSK2334470 + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of GSK2334470 sensitized an anaplastic thyroid cancer cell line harboring BRAF V600E and PIK3CA N1044S to Mekinist (trametinib) treatment as demonstrated by a reduction in viability in culture (PMID: 37713162). | 37713162 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37713162) | AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. | Full reference... |